Sign up for News by Email
All Releases
View Summary Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Aug 1, 2014
PDF 23.9 KB
View Summary Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma
Jul 9, 2014
PDF 56.0 KB
View Summary Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer
Jul 1, 2014
PDF 15.9 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies Global Healthcare Conference
May 30, 2014
PDF 9.5 KB
View Summary Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Recurrent Glioblastoma
May 30, 2014
PDF 18.7 KB
View Summary Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
May 30, 2014
PDF 18.8 KB
View Summary Threshold Announces Webcast of Analyst Event on Sunday, June 1, 2014
May 27, 2014
PDF 14.4 KB
View Summary Threshold Announces Clinical Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014
May 14, 2014
PDF 14.0 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference
May 13, 2014
PDF 9.4 KB
View Summary Threshold CEO Named as Finalist for European Inventor Award
May 6, 2014
PDF 8.6 KB
View Summary Threshold Pharmaceuticals Reports First Quarter 2014 Financial and Operational Results
May 1, 2014
PDF 23.2 KB
View Summary Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations of TH-302 With Immunotherapy, Antiangiogenic Therapy, and Radiotherapy to Be Presented at AACR Annual Meeting 2014
Apr 3, 2014
PDF 12.7 KB
View Summary Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer
Mar 27, 2014
PDF 14.0 KB
View Summary Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Mar 6, 2014
PDF 24.1 KB
View Summary Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Feb 20, 2014
PDF 9.7 KB
View Summary Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Dec 30, 2013
PDF 12.7 KB
View Summary Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Dec 7, 2013
PDF 16.8 KB
View Summary Threshold Pharmaceuticals Announces Presentation and Webcast at the Oppenheimer 24th Annual Healthcare Conference
Dec 3, 2013
PDF 9.2 KB
View Summary Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Nov 22, 2013
PDF 14.3 KB
View Summary Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be Presented at WFNO/SNO
Nov 11, 2013
PDF 11.7 KB
Showing 1-20 of 245 Page: 1 2 3 4 5 ... 13  Next 20
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue